Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of pegaptanib sodium in subfoveal choroidal neovascularization due to pathologic myopia
2007-005945-39Phase 2Active
- Sponsor
- Luigi Sacco University Hospital
- Start
- Jan 2008
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegaptanib sodium in myopic choroidal neovascularisation (mCNV) and myopic maculopathy (MM), sponsored by Luigi Sacco University Hospital. Primary endpoint: Safety of pegaptanib on visual acuity at 1 year. Started Jan 2008; status: active.
02
Drugs
pegaptanib sodium
03
Conditions
myopic choroidal neovascularisation (mCNV)myopic maculopathy (MM)
Beyond the preview
Go deeper on 2007-005945-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005945-39.